Dichotomous effects of C-C chemokines in HIV-1 pathogenesis

Immunology Letters

Volumn 110, Issue 1, 2007, Pages 1-5

  Ansari, A Wahid ^a   Heiken, Hans ^a   Moenkemeyer, Maren ^a   Schmidt, Reinhold E ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

C C chemokine receptor 5; Chemokine (C C motif) ligand 2; Co infection; HAART; HIV viremia; Homeostasis; Human immunodeficiency virus; Long term non progressors

Indexed keywords

BETA CHEMOKINE; CHEMOKINE; CHEMOKINE CCL4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; LIGAND; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; DISEASE COURSE; HEPATITIS G VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; INNATE IMMUNITY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TARGET CELL; TH2 CELL; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

CELL DIFFERENTIATION; CHEMOKINE CCL2; CHEMOKINES, CC; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, NATURAL; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, HIV; TH2 CELLS; VIRUS REPLICATION;

EID: 34247557582     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.02.012     Document Type: Review

References (45)

1. Rollins B.J. Chemokines Blood 90 (1997) 909-928
2. Moser B., and Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2 (2001) 123-128
3. Geras-Raaka E., Varma A., Ho H., Clark-Lewis I., and Gershengorn M.C. Human interferon-gamma-inducible protein 10 (IP-10) inhibits constitutive signaling of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. J Exp Med 188 (1998) 405-408
4. Berger E.A., Doms R.W., Fenyo E.M., Korber B.T., Littman D.R., Moore J.P., et al. A new classification for HIV-1. Nature 391 (1998) 240
5. Huang Y., Paxton W.A., Wolinsky S.M., Neumann A.U., Zhang L., He T., et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2 (1996) 1240-1243
6. Dean M., Carrington M., Winkler C., Huttley G.A., Smith M.W., Allikmets R., et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273 (1996) 1856-1862
7. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 (1996) 367-377
8. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382 (1996) 722-725
9. + T cells. Science 270 (1995) 1811-1815
10. Bleul C.C., Farzan M., Choe H., Parolin C., Clark-Lewis I., Sodroski J., et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382 (1996) 829-833
11. Oberlin E., Amara A., Bachelerie F., Bessia C., Virelizier J.L., Arenzana-Seisdedos F., et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382 (1996) 833-835
12. + individuals: correlation with a Th1-type cytokine response. Clin Exp Immunol 112 (1998) 92-99
13. Mack M., Luckow B., Nelson P.J., Cihak J., Simmons G., Clapham P.R., et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med 187 (1998) 1215-1224
14. Fatkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11 (2005) 1170-1172
15. Ansari A.W., Bhatnagar N., Dittrich-Breiholz O., Kracht M., Schmidt R.E., and Heiken H. Host chemokine (C-C motif) ligand-2 (CCL2) is differentially regulated in HIV type 1 (HIV-1)-infected individuals. Int Immunol 18 (2006) 1443-1451
16. Mengozzi M., De Filippi C., Transidico P., Biswas P., Cota M., Ghezzi S., et al. Human immunodeficiency virus replication induces monocyte chemotactic protein-1 in human macrophages and U937 promonocytic cells. Blood 93 (1999) 1851-1857
17. Hall D.J., Bates M.E., Guar L., Cronan M., Korpi N., and Bertics P.J. The role of p38 MAPK in rhinovirus-induced monocyte chemoattractant protein-1 production by monocytic-lineage cells. J Immunol 174 (2005) 8056-8063
18. Culley F.J., Pennycook A.M., Tregoning J.S., Hussell T., and Openshaw P.J. Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. J Virol 80 (2006) 4521-4527
19. Sui Y., Li S., Pinson D., Adany I., Li Z., Villinger F., et al. Simian human immunodeficiency virus-associated pneumonia correlates with increased expression of MCP-1, CXCL10, and viral RNA in the lungs of rhesus macaques. Am J Pathol 166 (2005) 355-365
20. Cinque P., Vago L., Mengozzi M., Torri V., Ceresa D., Vicenzi E., et al. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 12 (1998) 1327-1332
21. Monteiro de Almeida, Letendre S., Zimmerman J., Lazzaretto D., McCutchan A., and Ellis R. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J Neuroimmunol 169 (2005) 144-152
22. Pulliam L., Sun B., and Rempel H. Invasive chronic inflammatory monocyte phenotype in subjects with high HIV-1 viral load. J Neuroimmunol 157 (2004) 93-98
23. Carr M.W., Roth S.J., Luther E., Rose S.S., and Springer T. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 91 (1994) 3652-3656
24. Maghazachi A.A., Al Aoukaty A., and Schall T.J. C-C chemokines induce the chemotaxis of NK and IL-2-activated NK cells. Role for G proteins. J Immunol 153 (1994) 4969-4977
25. Matsushima K., Larsen C.G., DuBois G.C., and Oppenheim J.J. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 169 (1989) 1485-1490
26. Robertson M.J. Role of chemokines in the biology of natural killer cells. J Leukoc Biol 71 (2002) 173-183
27. Bonecchi R., Bianchi G., Bordignon P.P., D'Ambrosio D., Lang R., Borsatti A., et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 187 (1998) 129-134
28. Gu L., Tseng S., Horner R.M., Tam C., Loda M., and Rollins B.J. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404 (2000) 407-411
29. Sallusto F., Lenig D., Mackay C.R., and Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 187 (1998) 875-883
30. Van Coillie E., Van Damme J., and Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev 10 (1999) 61-86
31. Brown M.A., and Hural J. Functions of IL-4 and control of its expression. Crit Rev Immunol 17 (1997) 1-32
32. + T cells in multiple tissues during acute SIV infection. Nature 434 (2005) 1093-1097
33. Buchbinder S.P., Katz M.H., Hessol N.A., O'Malley P.M., and Holmberg S.D. Long-term HIV-1 infection without immunologic progression. AIDS 8 (1994) 1123-1128
34. Cao Y., Qin L., Zhang L., Safrit J., and Ho D.D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 332 (1995) 201-208
35. Pantaleo G., Menzo S., Vaccarezza M., Graziosi C., Cohen O.J., Demarest J.F., et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 332 (1995) 209-216
36. Ockenga J., Tillmann H.L., Trautwein C., Stoll M., Manns M.P., and Schmidt R.E. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol 27 (1997) 18-24
37. Telfer P.T., Brown D., Devereux H., Lee C.A., and DuSheiko G.M. HCV RNA levels and HIV infection: evidence for a viral interaction in haemophilic patients. Br J Haematol 88 (1994) 397-399
38. Leary T.P., Muerhoff A.S., Simons J.N., Pilot-Matias T.J., Erker J.C., Chalmers M.L., et al. Sequence and genomic organization of GBV-C: a novel member of the flaviviridae associated with human non-A-E hepatitis. J Med Virol 48 (1996) 60-67
39. Linnen J., Wages Jr. J., Zhang-Keck Z.Y., Fry K.E., Krawczynski K.Z., Alter H., et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 271 (1996) 505-508
40. Lefrere J.J., Roudot-Thoraval F., Morand-Joubert L., Brossard Y., Parnet-Mathieu F., Mariotti M., et al. Prevalence of GB virus type C/hepatitis G virus RNA and of anti-E2 in individuals at high or low risk for blood-borne or sexually transmitted viruses: evidence of sexual and parenteral transmission. Transfusion 39 (1999) 83-94
41. Heringlake S., Ockenga J., Tillmann H.L., Trautwein C., Meissner D., Stoll M., et al. GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients. J Infect Dis 177 (1998) 1723-1726
42. Tillmann H.L., Heiken H., Knapik-Botor A., Heringlake S., Ockenga J., Wilber J.C., et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 345 (2001) 715-724
43. Xiang J., Wunschmann S., Diekema D.J., Klinzman D., Patrick K.D., George S.L., et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 345 (2001) 707-714
44. Nattermann J., Nischalke H.D., Kupfer B., Rockstroh J., Hess L., Sauerbruch T., et al. Regulation of CC chemokine receptor 5 in hepatitis G virus infection. AIDS 17 (2003) 1457-1462
45. Xiang J., George S.L., Wunschmann S., Chang Q., Klinzman D., and Stapleton J.T. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1α, MIP-1β, and SDF-1. Lancet 363 (2004) 2040-2046